Back to Search
Start Over
Is OM-3 synergistic with GLP-2 in intestinal failure?
- Source :
-
The Journal of surgical research [J Surg Res] 2017 Jan; Vol. 207, pp. 7-12. Date of Electronic Publication: 2016 Aug 10. - Publication Year :
- 2017
-
Abstract
- Introduction: Glucagon-like peptide-2 (GLP-2) is a known intestinal growth factor that enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR). Luminal omega-3 (OM-3) has been shown to have some growth factor properties. It is possible that their mechanisms of action differ. Thus, we hypothesized that administering these two substances together may have a synergistic effect.<br />Methods: A total of 60 adult female Sprague-Dawley rats underwent 80% MSBR and divided as follows (n = 15/group): Saline (Control) + regular feeds; GLP-2 + regular feeds; Saline + OM-3 enriched feeds; and GLP-2 + OM-3 enriched feeds. Five animals per group were sacrificed at 7, 14, and 28 days. Small intestine mucosa was harvested. DNA and protein content were measured (mucosal mass markers) at all three time points. Galactose and Glycine absorption were measured (functional capacity markers) at 28 days. Statistical analysis was done by ANOVA with post hoc Tukey's HSD test.<br />Results: At all three time points, DNA was increased in all treatment groups compared to control (P < 0.05), but GLP-2 + OM-3 group did not have increased DNA content when compared to either treatments alone. At 7 and 14 d, all three treatment groups had increased protein content compared to control (P < 0.05). At 28 d, GLP-2 + OM-3 did not have increased protein content compared to control or individual treatments (P < 1.0). All three treatment groups had increased absorption of galactose and glycine compared to control (P < 0.05) but not each other.<br />Conclusions: Individually, GLP-2 and OM-3 are very effective in enhancing the adaptive process by increasing mucosal mass and function, at all three time points. More importantly, clinically, GLP-2 and OM-3 increase substrate absorption in a rat model of intestinal failure. However, the combination is not synergistic.<br /> (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Biomarkers metabolism
DNA metabolism
Drug Synergism
Drug Therapy, Combination
Fatty Acids, Omega-3 pharmacology
Female
Gastrointestinal Agents pharmacology
Glucagon-Like Peptide 2 pharmacology
Intestinal Absorption drug effects
Intestinal Mucosa drug effects
Intestinal Mucosa metabolism
Intestine, Small drug effects
Intestine, Small metabolism
Rats
Rats, Sprague-Dawley
Short Bowel Syndrome metabolism
Treatment Outcome
Fatty Acids, Omega-3 therapeutic use
Gastrointestinal Agents therapeutic use
Glucagon-Like Peptide 2 therapeutic use
Short Bowel Syndrome drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1095-8673
- Volume :
- 207
- Database :
- MEDLINE
- Journal :
- The Journal of surgical research
- Publication Type :
- Academic Journal
- Accession number :
- 27979490
- Full Text :
- https://doi.org/10.1016/j.jss.2016.08.018